| Fork head box C2is a transcription factor that belongs to the forkhead or wingedhelix family “C” subtribe. At present, the study of gene function of FOXC2mainlyconcentrated in its expression and mutation. It has a important role in growthdevelopment, cancer metastasis, diabetes, obesity and metabolic disease. FOXC2genecan improve the tumor cell invasion and metastasis through the EMT that wasmediated by many protein molecules and signaling pathway. Studies have shown thatFOXC2gene has a high expression not only in cervical cancer and ovarian cancertissues, but also mutated in a lot of congenital diseases. However, it expression inserum has less reported.Objective:The purpose of this experiment is to detect FOXC2protein expression andinfluence factors in serum of healthy women in every age group and patients whohave female reproductive system disease. We also explore the relationship betweenFOXC2concentration level and the happen of cervical cancer, endometrial cancer andepithelial ovarian cancer. This article provides a theoretical basis for whether FOXC2as a indicator for moitoring progress in gynecologic tumor disease or endometrisis.Methods:Using enzyme-liked immunosorbent experiment (ELISA) to detect FOXC2expression in serum of normal women in various age groups (cord blood32cases,90cases of children series,97cases of healthy women group) and analysis thedifferences between the three groups and influencing factors. Detection of the femalereproductive system tumor patients (68cases of cervical cancer,55cases ofendometrial cancer,45cases epithelial ovarian cancer) and benign disease patients (57cases of uterine fibroids, endometriosis50cases,26cases teratoma tumor, epithelialovarian tumor14cases) serum concentration of FOXC2level and contrast thedifferences among them. Analysis the relationship of FOXC2concentration that in patients’ general situation and patients’ cancer degree, tumor size and clinical stage.Compare the differences of serum FOXC2expression level in cancer patients beforeand after treatment.Result：1. Serum FOXC2concentration in umbilical cord blood group range from0.7213to27.7880ng/ml, the median is12.7876ng/ml; Serum FOXC2concentration inchildren group range from1.1138to49.6077ng/ml, the median is5.4493ng/ml;Serum FOXC2concentration in healthy women group range from1.2142to17.7705ng/ml, the median is5.2079ng/ml; FOXC2serum concentration in umbilical cordblood group and children was statistically significant difference (P=0.024); FOXC2serum concentration in umbilical cord blood group and healthy women group wasstatistically significant difference (P=0.014).2. Birth weight, maternal pregnancy hypertension, the maternal gestationaldiabetes, maternal serum pregnancy times for these factors did not influence theFOXC2concentrations in cord blood serum, the difference was not significant, had nostatistical significance (P>0.05).3. In the female reproductive system benign disease patients, serum FOXC2concentration in uterine fibroids group range from1.1823to62.9591ng/ml, themedian is5.7438ng/ml; Serum FOXC2concentration in endometriosis patients grouprange from2.2301to49.6218ng/ml, the median is6.1619ng/ml; Serum FOXC2concentration in maturity teratoma patients group range from0.7554to46.5693ng/ml,the median is5.5825ng/ml; Serum FOXC2concentration in benign epithelial ovariantumor patients group range from0.5974to26.9036ng/ml, the median is5.4943ng/ml.Endometriosis patients serum FOXC2concentration was significantly higher than thatin healthy women, with statistical significance (P<0.05). But by statistical analysis,uterine fibroids, mature teratoma patients, benign epithelial ovarian cancer patientsserum FOXC2concentration was not significantly difference compared with healthywomen, no statistically significant (P>0.05).4. The concentration of serum FOXC2in patients with endometriosis than instage Ⅰ～Ⅱ and Ⅲ～Ⅳ did not show significant difference, no statisticalsignificance (P>0.05); The healthy adult group had statistically significant comparedwith the Ⅲ～Ⅳ grade (P<0.05);5. There is no significant difference in serum FOXC2concentrations between patients with ovarian endometriosis and peritoneal endometriosis (P>0.05). The levelsof FOXC2in serum of healthy control group were significantly different from that ofmature tumor and epithelial tumor, and were not significantly different from that ofhealthy controls (P>0.05).6. In the female reproductive system tumor patients, serum FOXC2concentration in cervical cancer group range from0.8335to53.9984ng/ml, themedian is4.5924ng/ml; Serum FOXC2concentration in endometrial cancer grouprange from0.5130to59.2814ng/ml, the median is6.2877ng/ml; Serum FOXC2concentration in epithelial ovarian cancer group range from0.4999to31.2785ng/ml,the median is6.4361ng/ml;7. Through statistical analysis, the patients with cervical cancer, endometrialcancer, serum FOXC2in patients with epithelial ovarian cancer patients comparedwith healthy control group concentration,did not show significant difference, nostatistical significance (P>0.05).8. In cervical cancer, cervical squamous carcinoma patients compared withadenocarcinoma and gland scale cancer patients, FOXC2serum concentration is lowand there were statistically significant (P<0.05). But serum FOXC2concentration hasno statistical significance in patients with cervical cancer differentiation degree, thetumor size, clinical stage, lymph node metastasis and vascular metastasis differenceshad no statistical significance (P>0.05).9. The serum concentrations of FOXC2in patients with cervical adenocarcinomawere significantly different from healthy controls, and were statistically significant（P<0.05）.There was no significant difference between before and after treatment ofcervical carcinoma (P>0.05).10. Serum FOXC2concentrations have no relative to cervical cancer patients’age, BMI, menopausal status, hypertension, diabetes, smoking history and familyhistory of cancer, there were no statistical significance (P>0.05).11. In endometrial carcinoma, the concentration of serum FOXC2in patientswith low endometrial differentiation was significantly higher than in highdifferentiation, the difference was significant, with statistical significance (P<0.05)and there were no statistical significance in the pathological type, pathologic stage,myometrial invasion, lymph metastasis and vascular transfer related (P>0.05).12. The concentrations of serum FOXC2in patients with non endometrial adenocarcinoma were significantly different from healthy controls (P<0.05). Therewas no significant difference in the treatment of endometrial carcinoma (P>0.05).13. Serum FOXC2concentrations have no relative to endometrial cancerpatients’ age, BMI, menopausal status, hypertension, diabetes, smoking history andfamily history of cancer, there were no statistical significance (P>0.05).14. In epithelial ovarian cancer patients, serum FOXC2expression in patientswith diabetes was higher than patients without diabetes, significant difference wasstatistically significant (P<0.05). The healthy control group and the epithelial ovariancancer patients with diabetes mellitus, the diabetes mellitus patients with diabetesmellitus were significantly higher than those in the healthy control group, thedifference was statistically significant （P<0.05）;15. Serum FOXC2concentrations have no relative to ovarian cancer patients’ age,BMI, menopausal status, hypertension, diabetes, smoking history and family historyof cancer, there were no statistical significance (P>0.05).16. Serum FOXC2concentration in patients with epithelial ovarian cancer ofpathological type, differentiation degree, tumor size, clinical stage, lymph node metastasisand vascular metastasis difference was not significant (P>0.05). There were no statisticalsignificance in before and after treatment of endometrial cancer.(P>0.05)Conclusion1. Fetal blood FOXC2was highly expressed before birth.2. The expression of FOXC2increased in patients with endometriosis III-Ⅳphase.3. The serum levels of FOXC2were related to the pathological types of cervicalcancer, and the expression levels of adenocarcinoma increased.4. The expression of FOXC2in the patients with poorly differentiatedendometrial carcinoma increased.5. The concentrations of serum FOXC2in patients with non endometrialadenocarcinoma were higher than those of healthy adults.6. The content of FOXC2in serum of patients with ovarian cancer, squamouscell carcinoma of the cervix and the high differentiation endometrial carcinoma hadno significant difference with that of the same age group. |
PDF Full Text Request